Which endpoints should we use in evaluating the use of novel fluoropyrimidine regimens in colorectal cancer?TWELVES, C. J; CASSIDY, J.British journal of cancer. 2002, Vol 86, Num 11, pp 1670-1676, issn 0007-0920Article

The rational development of capecitabine from the laboratory to the clinicPENTHEROUDAKIS, G; TWELVES, C.Anticancer research. 2002, Vol 22, Num 6B, pp 3589-3596, issn 0250-7005, 8 p.Article

QUANTITATIVE SIGNIFICANCE OF HYPOXIC VASOCONSTRICTION IN THE FERRET LUNGSUGGETT AJ; MOHAMMED FH; BARER GR et al.1981; RESPIR. PHYSIOL.; ISSN 0034-5687; NLD; DA. 1981; VOL. 46; NO 2; PP. 89-104; BIBL. 2 P.Article

Capecitabine as first-line treatment in colorectal cancer: pooled data from two large, phase III trialsTWELVES, C.European journal of cancer. Supplement (1990). 2002, Vol 38, Num 2, pp S15-S20, issn 1359-6349Article

Oral cancer treatment: developments in chemotherapy and beyondO'NEILL, V. J; TWELVES, C. J.British journal of cancer. 2002, Vol 87, Num 9, pp 933-937, issn 0007-0920, 5 p.Article

Phase I/II study of DHA-paclitaxel in combination with carboplatin in patients with advanced malignant solid tumoursHARRIES, M; O'DONNELL, A; SCURR, M et al.British journal of cancer. 2004, Vol 91, Num 9, pp 1651-1655, issn 0007-0920, 5 p.Article

A phase I clinical and pharmacokinetic study of the new topoisomerase inhibitor GI147211 given as a 72-h continuous infusionPAZ-ARES, L; KUNKA, R; WISSEL, P et al.British journal of cancer. 1998, Vol 78, Num 10, pp 1329-1336, issn 0007-0920Article

What is the effect of adjusting epirubicin doses for body surface area?DOBBS, N. A; TWELVES, C. J.British journal of cancer. 1998, Vol 78, Num 5, pp 662-666, issn 0007-0920Article

Acute reversible neurological deficit following intrathecal chemotherapyDUNKELMAN, H; EARL, H. M; TWELVES, C et al.Cancer chemotherapy and pharmacology. 1991, Vol 27, Num 4, pp 329-330, issn 0344-5704, 2 p.Article

Measurement of epidoxorubicin and its metabolites by high-performance liquid chromatography using an advanced automated sample processorDOBBS, N. A; TWELVES, C. J.Journal of chromatography. Biomedical applications. 1991, Vol 572, Num 1-2, pp 211-217, issn 0378-4347Article

A randomised cross-over trial comparing patient preference for oral capecitabine and 5-fluorouracil/leucovorin regimens in patients with advanced colorectal cancerTWELVES, C; GOLLINS, S; GRIEVE, R et al.Annals of oncology. 2006, Vol 17, Num 2, pp 239-245, issn 0923-7534, 7 p.Article

Anthracycline doses in patients with liver dysfunction : do UK oncologists follow current recommendations?DOBBS, N. A; TWELVES, C. J.British journal of cancer. 1998, Vol 77, Num 7, pp 1145-1148, issn 0007-0920Article

The oral fluorinated pyrimidinesDE BONO, J. S; TWELVES, C. J.Investigational new drugs. 2001, Vol 19, Num 1, pp 41-59, issn 0167-6997Article

Haematological recovery following high-dose cyclophosphamide with autologous bone marrow transplantationTWELVES, C; SOUHAMI, R; HARPER, P et al.Cancer chemotherapy and pharmacology. 1989, Vol 25, Num 3, pp 213-218, issn 0344-5704Article

Efficacy of capecitabine versus 5-fluorouracil in colorectal and gastric cancers: a meta-analysis of individual data from 6171 patientsCASSIDY, J; SALTZ, L; TWELVES, C et al.Annals of oncology. 2011, Vol 22, Num 12, pp 2604-2609, issn 0923-7534, 6 p.Article

Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer : the X-ACT trialCASSIDY, J; DOUILLARD, J.-Y; COXON, F et al.British journal of cancer. 2006, Vol 94, Num 8, pp 1122-1129, issn 0007-0920, 8 p.Article

Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European organization for research and treatment of cancer 10961 multicenter phase III trialBIGANZOLI, L; CUFER, T; LOHRISCH, C et al.Journal of clinical oncology. 2002, Vol 20, Num 14, pp 3114-3121, issn 0732-183XArticle

Phase II study of XR5000 (DACA) administered as a 120-h infusion in patients with recurrent glioblastoma multiformeTWELVES, C; CAMPONE, M; FUMOLEAU, P et al.Annals of oncology. 2002, Vol 13, Num 5, pp 777-780, issn 0923-7534Article

A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumoursPRONK, L. C; VASEY, P; SPARREBOOM, A et al.British journal of cancer. 2000, Vol 83, Num 1, pp 22-29, issn 0007-0920Article

Bioequivalence of two tablet formulations of capecitabine and exploration of age, gender, body surface area, and creatinine clearance as factors influencing systemic exposure in cancer patientsCASSIDY, J; TWELVES, C; BUSH, E et al.Cancer chemotherapy and pharmacology. 1999, Vol 44, Num 6, pp 453-460, issn 0344-5704Article

Activity of doxorubicin covalently bound to a novel human serum albumin microcapsuleEATOCK, M; CHURCH, N; HARRIS, R et al.Investigational new drugs. 1999, Vol 17, Num 2, pp 111-120, issn 0167-6997Article

Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacyTWELVES, C; SCHEITHAUER, W; MCKENDRICK, J et al.Annals of oncology. 2012, Vol 23, Num 5, pp 1190-1197, issn 0923-7534, 8 p.Article

Prediction of early death among patients enrolled in phase I trials: development and validation of a new model based on platelet count and albuminPLOQUIN, A; OLMOS, D; VOEST, E. E et al.British journal of cancer. 2012, Vol 107, Num 7, pp 1025-1030, issn 0007-0920, 6 p.Article

Erlotinib in combination with pemetrexed for patients with advanced non-small-cell lung cancer (NSCLC): a phase I dose-finding studyRANSON, M; RECK, M; ANTHONEY, A et al.Annals of oncology. 2010, Vol 21, Num 11, pp 2233-2239, issn 0923-7534, 7 p.Article

A Dynamic Model of Hand-and-Foot Syndrome in Patients Receiving CapecitabineHENIN, E; YOU, B; TOD, M et al.Clinical pharmacology and therapeutics. 2009, Vol 85, Num 4, pp 418-425, issn 0009-9236, 8 p.Article